Development of diphenyl-1,2,4-oxadiazole analogues as allosteric modulators of the rxfp3 receptor

Abstract

Relaxin-3/RXFP3 antagonism is a novel strategy for drug development to treat alcohol use disorder (AUD). We recently discovered the first-in-class RXFP3 negative allosteric modulators (NAMs), represented by RLX-33, which significantly reduced alcohol consumption in rats. In this study, we report the design and synthesis of a series of diphenyl-1,2,4-oxadiazole analogues derived from RLX-33. Structure–activity relationship studies of sites A and B of RLX-33 revealed that the aromatic ring at site A is not required for RXFP3 allosteric modulation and the pyrrolidone linker at site B could be replaced with a cyclic or linear alkylamine. Compound (R,R)-3 has improved potency and ADME properties (e.g., solubility and metabolic stability) compared to RLX-33, while maintaining high receptor subtype selectivity over RXFP1 and RXFP4. Importantly, (R,R)-3 significantly attenuated alcohol self-administration without affecting sucrose self-administration and general locomotor activity in rats, demonstrating the potential of RXFP3 NAMs as promising drug candidates for AUD.